Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program

Journal of Addictive Diseases

Volumn 15, Issue 1, 1996, Pages 93-104

  Gourevitch, Marc N ^a,c   Wasserman, William ^a   Panero, Maria S ^a   Selwyn, Peter A ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; DRUG MISUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; PROPHYLAXIS; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTITUBERCULAR AGENTS; COMORBIDITY; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; TUBERCULOSIS;

EID: 0029876493     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v15n01_07     Document Type: Article

References (48)

1. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989; 321:874-9.
2. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med. 1979; 139:337-9.
3. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-50.
4. Centers for Disease Control. Screening for tuberculosis and tuberculous infection in high-risk populations; and the use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR. 1990;39(no. RR-8):1-12.
5. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HTV. Ann Intern Med. 1993; 119:194-8.
6. Genewein A, Telenti A, Bernasconi C, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet. 1993;342:841-4.
7. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268:504-9.
8. Centers for Disease Control and Prevention. Approaches to improving adherence to antituberculosis therapy-South Carolina and New York, 1986-1991. MMWR. 1993;42:74-75,81.
9. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis. 1986; 134:355-363.
10. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO. 1982;60:555-64.
11. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970; 17:28-106.
12. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-72.
13. Weis SE, Slogum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994; 330:1179-84.
14. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS. 1994;8:1103-8.
15. Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest. 1979;76:741-3.
16. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med. 1993;328:576-8.
17. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis. 1992;146:1623-33.
18. Frieden TR, Sterling T, Pablos-Mendez A, Kilbum JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328:521-6.
19. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis. 1991;144:745-9.
20. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med. 1989;111:761-3.
21. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Pub Health Rep. 1993;108:492-500.
22. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis. 1990;142:725-35.
23. Kniker WT, Anderson CT, McBryde JL, Roumiantzeff M, Lesourd B. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the U.S.A. Ann Allergy. 1984;52:75-82.
24. Selvin S. Statistical analysis of epidemiologic data. New York: Oxford University Press, 1991.
25. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327:1697-703.
26. Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the advisory committee for the elimination of tuberculosis (ACET). MMWR. 1989;38:236-50.
27. Haverkos HW. Infectious diseases and drug abuse: prevention and treatment in the drug abuse treatment system. J Subst Abuse Treat. 1991;8:269-75.
28. Centers for Disease Control. Improving patient compliance in tuberculosis treatment programs. 1989:3-4.
29. Vennema A. Contact investigation and isoniazid chemoprophylaxis in New York City, 1979-1987. NY State J Med. 1992;92:185-8.
30. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA. 1993;270:65-8.
31. Drucker E. Molecular epidemiology meets the fourth world. Lancet. 1993;342:817-8.
32. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers: a decision analysis. JAMA. 1991;265:2987-91.
33. Wadhawan D, Hira S, Mwansa N, Sunkutu R, Adera T, Perine P. Preventive tuberculosis chemotherapy with isoniazid (INH) among patients infected with HIV-1. IX International Conference on AIDS, Berlin, June 1993 (Abstract POB07-1114).
34. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med. 1991;6:35-40.
35. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:1412-6.
36. Rosenberg PS, Gail MH, Schrager LK, et al. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. J Acquir Immune Defic Syndr. 1991;4:392-401.
37. Curry F. Neighborhood clinics for more effective outpatient control of tuberculosis. N Engl J Med. 1968;279:1262-7.
38. O'Connor PG, Melde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med. 1992;93:382-6.
39. McDonald RJ, Memon AM, Reichman LB. Successful supervised ambulatory management of tuberculosis treatment failures. Ann Intern Med. 1982; 96:297-302.
40. Elk R, Grabowski J, Rhoades H, Spiga R, Schmitz J, Jennings W. Compliance with tuberculosis treatment in methadone-maintained patients: behavioral interventions. J Subst Abuse Treat 1993;10:371-82.
41. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Des Jarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Pub Health Rep. 1992;109:319-27.
42. Schlenger WE, Kroutil LA, Roland EJ, Dennis ML. National evaluation of models for linking drug abuse treatment and primary care. Research Triangle Park, NC: Research Triangle Institute, 1992.
43. Lowinson JH, Marion IJ, Joseph H, Dole VR Methadone maintenance. In: Lowinson J, Ruiz P, Millman R, Langrod J, eds. Substance Abuse: A Comprehensive Textbook. New York: Williams & Wilkins; 1992:550.
44. Novick DM, Gelb AM, Stenger RJ, et al. Hepatitis B serologic studies in narcotic users with chronic liver disease. Am J Gastroenterol. 1981;75:111-5.
45. Sbarboro JA. Pulbic health aspects of tuberculosis: supervison of therapy. Clin Chest Med. 1980; 1:253-63.
46. Fox W. Self-administration, of medicaments: A review of published work and a study of the problems. Bull Int Union Tuberc. 1961; 32:307-31.
47. Moulding T, Onstad GD, Sbarbaro JA. Supervision of outpatient drug therapy with the medication monitor. Ann Intern Med. 1970;73:559-64.
48. Alcabes P, Vossenas P, Cohen R, Braslow C, Michaels D, Zoloth S. Compliance with isoniazid prophylaxis in jail. Am Rev Respir Dis. 1989;140:1194-7.